Nathalie Mason
Clinical Researcher
Data updated
Research Footprint
Nathalie Mason appears in 45 tracked papers (2018–2026), most studied alongside Psilocybin, Ayahuasca and LSD, across Healthy Volunteers, Depressive Disorders and Anxiety Disorders.
Most-cited paper: Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin (258 citations).
Frequent co-authors: Johannes Ramaekers, Kim Kuypers and Jan Reckweg.
Background & Research
Dr. Nathalie Mason is a clinical researcher specialising in human experimental psychopharmacology and early-phase clinical trials of psychedelic compounds. Her work spans controlled laboratory studies in healthy volunteers and phase 1/2 clinical investigations in patients, with a particular focus on classical serotonergic psychedelics (psilocybin, LSD) and rapidly acting tryptamines (notably inhaled 5‑MeO‑DMT). She has been involved in placebo-controlled and dose-ranging studies that probe acute subjective effects, pain perception, immune changes, and safety/tolerability profiles, and in translational trials assessing a vapourised 5‑MeO‑DMT formulation (GH001) for treatment‑resistant depression.
Key Impact
Notable for experimental and early-phase clinical studies characterising the subjective, physiological and potential therapeutic effects of classical psychedelics and novel tryptamines in humans.
Collaboration Network
62 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Nathalie Mason is associated with.